The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Editor

Share

Personal info

View

Links

Table of contents

About

Terms

 

Alan K. Burnett

Department of Haematology

Cardiff University School of Medicine

Cardiff

UK

[email]@cardiff.ac.uk

Name/email consistency: high

 
 
 
 
 
 
 

Affiliation

  • Department of Haematology, Cardiff University School of Medicine, Cardiff, UK. 1999 - 2012

References

  1. The addition of the farnesyl transferase inhibitor, tipifarnib, to low dose cytarabine does not improve outcome for older patients with AML. Burnett, A.K., Russell, N.H., Culligan, D., Cavanagh, J., Kell, J., Wheatley, K., Virchis, A., Hills, R.K., Milligan, D. Br. J. Haematol. (2012) [Pubmed]
  2. Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia. Burnett, A.K., Russell, N.H., Hills, R.K., Kell, J., Freeman, S., Kjeldsen, L., Hunter, A.E., Yin, J., Craddock, C.F., Dufva, I.H., Wheatley, K., Milligan, D. J. Clin. Oncol. (2012) [Pubmed]
  3. Who should be transplanted in first remission of acute myeloid leukaemia? Burnett, A.K., Hills, R.K. Curr. Treat. Options. Oncol (2011) [Pubmed]
  4. Therapeutic advances in acute myeloid leukemia. Burnett, A., Wetzler, M., Löwenberg, B. J. Clin. Oncol. (2011) [Pubmed]
  5. Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial. Burnett, A.K., Hills, R.K., Milligan, D., Kjeldsen, L., Kell, J., Russell, N.H., Yin, J.A., Hunter, A., Goldstone, A.H., Wheatley, K. J. Clin. Oncol. (2011) [Pubmed]
  6. European development of clofarabine as treatment for older patients with acute myeloid leukemia considered unsuitable for intensive chemotherapy. Burnett, A.K., Russell, N.H., Kell, J., Dennis, M., Milligan, D., Paolini, S., Yin, J., Culligan, D., Johnston, P., Murphy, J., McMullin, M.F., Hunter, A., Das-Gupta, E., Clark, R., Carr, R., Hills, R.K. J. Clin. Oncol. (2010) [Pubmed]
  7. The impact on outcome of the addition of all-trans retinoic acid to intensive chemotherapy in younger patients with nonacute promyelocytic acute myeloid leukemia: overall results and results in genotypic subgroups defined by mutations in NPM1, FLT3, and CEBPA. Burnett, A.K., Hills, R.K., Green, C., Jenkinson, S., Koo, K., Patel, Y., Guy, C., Gilkes, A., Milligan, D.W., Goldstone, A.H., Prentice, A.G., Wheatley, K., Linch, D.C., Gale, R.E. Blood (2010) [Pubmed]
  8. Attempts to optimize induction and consolidation treatment in acute myeloid leukemia: results of the MRC AML12 trial. Burnett, A.K., Hills, R.K., Milligan, D.W., Goldstone, A.H., Prentice, A.G., McMullin, M.F., Duncombe, A., Gibson, B., Wheatley, K. J. Clin. Oncol. (2010) [Pubmed]
  9. The impact of dose escalation and resistance modulation in older patients with acute myeloid leukaemia and high risk myelodysplastic syndrome: the results of the LRF AML14 trial. Burnett, A.K., Milligan, D., Goldstone, A., Prentice, A., McMullin, M.F., Dennis, M., Sellwood, E., Pallis, M., Russell, N., Hills, R.K., Wheatley, K. Br. J. Haematol. (2009) [Pubmed]
  10. Tipifarnib in acute myeloid leukemia. Burnett, A.K., Kell, J. Drugs. Today (2007) [Pubmed]
  11. Targeting treatment in AML. Burnett, A.K., Knapper, S. Hematology. Am. Soc. Hematol. Educ. Program (2007) [Pubmed]
  12. Treatment of older patients with acute myeloid leukemia--new agents. Burnett, A.K., Mohite, U. Semin. Hematol. (2006) [Pubmed]
  13. Long-term results of the MRC AML10 trial. Burnett, A.K., Wheatley, K., Goldstone, A.H., Stevens, R., Hann, I., Hills, R.K. Clin. Adv. Hematol. Oncol (2006) [Pubmed]
  14. Acute myeloid leukemia: treatment of adults under 60 years. Burnett, A.K. Rev. Clin. Exp. Hematol (2002) [Pubmed]
  15. Current controversies: which patients with acute myeloid leukaemia should receive a bone marrow transplantation?--an adult treater's view. Burnett, A.K. Br. J. Haematol. (2002) [Pubmed]
  16. The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse: results of the UK MRC AML 10 trial. Burnett, A.K., Wheatley, K., Goldstone, A.H., Stevens, R.F., Hann, I.M., Rees, J.H., Harrison, G. Br. J. Haematol. (2002) [Pubmed]
  17. Evaluating the contribution of allogeneic and autologous transplantation to the management of acute myeloid leukemia in adults. Burnett, A.K. Cancer Chemother. Pharmacol. (2001) [Pubmed]
  18. High dose cytarabine or transplantation for consolidation of younger patients with acute myeloid leukemia. Burnett, A.K., Kell, J. Curr. Opin. Oncol (2000) [Pubmed]
  19. Acute myeloid leukemia: therapeutic indications. Burnett, A.K., Kell, J., Rowntree, C. Curr. Opin. Hematol. (2000) [Pubmed]
  20. Presenting white blood cell count and kinetics of molecular remission predict prognosis in acute promyelocytic leukemia treated with all-trans retinoic acid: result of the Randomized MRC Trial. Burnett, A.K., Grimwade, D., Solomon, E., Wheatley, K., Goldstone, A.H. Blood (1999) [Pubmed]
 
WikiGenes - Universities